Followers | 19 |
Posts | 6073 |
Boards Moderated | 3 |
Alias Born | 05/23/2019 |
![](https://investorshub.advfn.com/uicon/712755.png?cb=1666718157)
Thursday, February 25, 2021 1:54:00 PM
Wolf Says;
The 20 plus million acquisition and 24 new employees will definitely affect the bottom line including the new medical chiefs salary. How much salary for these people is it going to add up to?
Dr. Joong J Fang Said;
Look at the bright side. If the trials become a bust at least this company can go into a new business which the acquisition will offer You Understand.
JR needs to start showing some more energy in interviews, or hire someone that can. His last few appearances have been extremely underwhelming. Today has been a great day for CMPS as their market cap has now surpassed the $2 billion barrier. In my opinion MMEDF should have a similar market cap, putting us right around the $6 mark. However, we need some energy. Based on predictions I've read we should be on the NASDAQ sometime between 1 and 72 months. Everyone seems to think they know the date. Unfortunately, we're going to need some catalysts other than that. We can't just hang our hat on a listing. We have significantly more potential than CMPS, what gives?
Recent MNMD News
- MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer • Business Wire • 07/29/2024 11:00:00 AM
- MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT) • Business Wire • 07/17/2024 11:00:00 AM
- MindMed to be Included in Russell 2000® and Russell 3000® Indexes • Business Wire • 06/28/2024 11:00:00 AM
- MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • Business Wire • 06/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:00:10 PM
- MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) • Business Wire • 06/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:30:10 PM
- MindMed to Participate in June Conferences • Business Wire • 05/28/2024 11:00:00 AM
- MindMed to Participate at May Investor Conferences • Business Wire • 05/09/2024 08:01:00 PM
- New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US • Business Wire • 05/09/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:15:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:10:12 PM
- MindMed Reports First Quarter 2024 Financial Results and Business Updates • Business Wire • 05/08/2024 08:01:00 PM
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York • Business Wire • 05/04/2024 12:00:00 PM
- MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update • Business Wire • 05/02/2024 11:00:00 AM
- MindMed to Present at Upcoming May Medical Conferences • Business Wire • 04/25/2024 11:00:00 AM
- MindMed to Present at Upcoming April Medical Conferences • Business Wire • 04/02/2024 11:00:00 AM
- MindMed Announces Voluntary Delisting from Cboe Canada • Business Wire • 04/01/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:32:03 PM
- MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference • Business Wire • 03/11/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:19:43 PM
- Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement • Business Wire • 03/07/2024 12:13:00 PM
- Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)] • Edgar (US Regulatory) • 03/07/2024 12:09:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:56:00 AM
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder • Business Wire • 03/07/2024 11:00:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM
Kona Gold Beverage Significantly Reduces Debt from Multiple Holders • KGKG • Jul 31, 2024 9:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • ELMGF • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM